Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2012 Nov 19;30(49):7097-104. doi: 10.1016/j.vaccine.2012.09.040. Epub 2012 Sep 28.

The potential economic value of a human norovirus vaccine for the United States.

Author information

1
Public Health Computational and Operations Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Abstract

Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.

PMID:
23026689
PMCID:
PMC3517973
DOI:
10.1016/j.vaccine.2012.09.040
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center